Oxurion NV (formerly known as ThromboGenics NV), a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
New checkpoint inhibitor on the block
Latest NewsResearchers at Austrian IMBA have identified a well-known co-factor of amino acid synthesis and monoamine neurotransmitter synthesis to play a prominent role in the development of autoimmunity and cancer.
BIO-Europe: advanced therapies in focus
Latest NewsGene and cell therapies, pediatric drugs, and formulation were just some hot topics discussed in a record number of B2B meetings at BIO-Europe in Copenhagen.
Dry AMD: Oxurion licences heparanase blockers from Beta Therapeutics
Latest NewsOxurion NV and Beta Therapeutics Inc have inked an R&D agreement aimed to develop new heparanase inhibitors to treat dry AMD.
Nanobots heading to eye delivery
Latest NewsGerman researchers have developed a drug delivery nanobot that can propel through the eye.
Next 9th European Biotechnology Science & Industry Guide 2019!
Sponsored PublicationsIn March, the 9th edition of the "European Biotechnology Science & Industry Guide" will be published and distributed at BIO Europe Spring conference 2019 in Vienna. The B2B handbook presents companies and institutions in the fields of Biotech, Biopharma, BioServices and BioManufacturing an ideal medium with which new customers and investors can find you. The previous edition can be found here.
Argenx antibody kills AML
Latest NewsSanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammation
Latest NewsSanofi has acquired the global commercialisation rights for two preclinical programmes from Denali Therapeutics.
Adrienne Graves joins Oxurion’s Board
AppointmentsOxurion NV (formerly known as ThromboGenics NV), a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye, announced today the appointment of Adrienne Graves, Ph.D., to its board of directors. Dr. Graves will replace Paul Howes, who has been a board member since 2014.
ProQR in licence deal with Ionis Pharmaceuticals
Latest NewsFully human antibodies for advanced immunotherapies
BackgroundAnswering the increasing demand for novel fully human antibodies in immunotherapy, German biotech pioneer YUMAB GmbH accelerates drug discovery and development with a comprehensive and versatile technology platform.